Generic Name and Formulations:
Mesalamine 1g; supps.
Indications for CANASA:
Mild-to-moderately active ulcerative proctitis.
Retain supp in rectum for at least 1–3hrs. 1g once daily at bedtime. Treat for 3–6 weeks.
Sulfasalazine or aspirin allergy. Renal or hepatic impairment. Evaluate renal function before starting and periodically during therapy. Monitor for acute intolerance syndrome; discontinue if suspected. May stain clothes. Elderly. Pregnancy. Nursing mothers.
Concomitant nephrotoxic agents (eg, NSAIDs) may increase risk of renal effects; monitor. Concomitant azathioprine or 6-mercaptopurine may increase risk of blood disorders; if unavoidable, monitor CBCs and platelets. May interfere with measurements by liquid chromatography of urinary normetanephrine; consider other alternative assay.
Dizziness, rectal pain, fever, rash, acne, colitis, headache, flatulence, abdominal pain, diarrhea, nausea; mesalamine-induced acute intolerance syndrome, hypersensitivity reactions (including myocarditis, pericarditis, pneumonitis, hematologic abnormalities), renal or hepatic failure.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Models Predict Intracerebral Hemorrhage Growth
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy